Active ingredient: Ambrisentan 

 

Form/Route: Tablet/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 

Design: Single-dose, two-way, crossover in vivo 

Strength: 10 mg 

Subjects: Healthy males, general population. 

Additional comments: Due to the risk of teratogenicity of ambrisentan, the study should be 
conducted in healthy male volunteers. Letairis® (ambrisentan) Tablets was approved with 
a Risk Evaluation and Mitigation Strategy (REMS), which restricts its use. All pertinent 
elements of the REMS must be incorporated into the protocol and informed consent. 

______________________________________________________________________________ 

 

2. Type of study: Fed 

Design: Single-dose, two-way, crossover in vivo 

Strength: 10 mg 

Subjects: Healthy males, general population. 

Additional Comments: Please see comment above. Please refer to the Amantadine 
Hydrochloride Tablet Draft Guidance for additional information regarding fed studies. 

______________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Ambrisentan in plasma 

 

Bioequivalence based on (90% CI): Ambrisentan 

 

Waiver request of in vivo testing: 5 mg based on (i) acceptable bioequivalence studies on the 
10 mg strength, (ii) acceptable in vitro dissolution testing of all strengths, and (iii) proportional 
similarity of the formulations across all strengths. Please refer to the Mirtazapine Tablet Draft 
Guidance for additional information regarding waivers of in-vivo testing 

 

Dissolution test method and sampling times: 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution 
information for this product at this website. Please conduct comparative dissolution testing on 12 
dosage units each of all strengths of the test and reference products. Specifications will be 
determined upon review of the application 


